Observe the curative effect of n-Butyl cyanoacrylate injection in treating laryngopharynx hemangioma.
- Author:
Weimin LI
1
;
Bo FENG
;
Jialing WANG
;
Wenming WU
;
Liangfa LIU
;
Rongguang WANG
;
Dongyan HUANG
Author Information
1. Department of Otolaryngology-Head and Neck Surgery, General Hospital of PLA, Beijing, 100853, China. Liweimin301@163.com
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Child;
Embolization, Therapeutic;
Enbucrilate;
administration & dosage;
therapeutic use;
Female;
Hemangioma;
therapy;
Humans;
Laryngoscopy;
Male;
Middle Aged;
Pharyngeal Neoplasms;
therapy;
Treatment Outcome;
Young Adult
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2008;22(24):1120-1122
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the clinical effectiveness of injection n-Butyl cyanoacrylate (NBCA) in treating laryngopharynx hemangioma.
METHOD:Thirty cases of laryngopharynx hemangioma who received NBCA injection were obtained from our department 1998-2007. Twenty-five cases had tracheotomy under General anesthesia, and NBCA was injected into hemangioma by direct laryngoscopy. NBCA was mixed with iodide, and the concentration was 25.00% to 33.33%, NBCA dosage was 0.5 ml to 2.0 ml. There were 5 cases whose hemangioma confined to oropharynx didn't have tracheotomy, and they were injected straightly with the speculum oris. We observed the shedding of hemangioma in different time.
RESULT:Hemangioma with diameter less than 1 cm, shedded in about 1 month. However, hemangioma with diameter more than 4 cm, shedded in a period more than 3.5 month. No recurrence was observed in the follow up of 3 months to seven years.
CONCLUSION:Avoiding dissection of neck and repetitious operation, NBCA injection could be a safe, simple and effective therapy for laryngopharynx hemangioma.
